Although 12 month results did not meet the primary endpoint, the study continued following the predefined study protocol with a comprehensive final analysis on treatment conducted at 18 months.
The final analysis of the study demonstrated a statistically significant slowing of disease progression on the Alzheimer's disease composite score (ADCOMS) after 18 months of treatment in patients receiving the highest treatment dose of 10 mg/kg twice a month and reduction of amyloid accumulated in the brain as measured by using amyloid positron emission tomography (PET).
Dose-dependent changes from baseline were observed across the PET results and the clinical endpoints. Further, the highest treatment dose of BAN2401 began to show statistically significant clinical benefit as measured by ADCOMS as early as 6 months including at 12 months.
BAN2401, a humanized monoclonal antibody, selectively binds to toxic amyloid-beta aggregates that are thought to contribute to the neurodegenerative process in Alzheimer's disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease.
BioArctic is focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company is also developing a potential treatment for complete spinal cord injury.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval